Prophylactic Vs. Therapeutic Use of Uroxatrol in Men Undergoing Brachytherapy

• Status: Unknown status
• Trial end date: 2005-09-01
• Target enrollment: 0
• Participant gender: Male

Summary

To asess the efficacy of Uroxatrol, an alpha blocker in men undergoing prostate brachytherapy to treat prostate cancer, and whether the use of Uroxatrol in advance of the brachytherapy is better or not than starting it on the day of surgery.

• Phase: Phase 3
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: New York Prostate Institute
• Collaborator: Sanofi
• Treatments: Alfuzosin

Criteria

Inclusion Criteria:

• 1) Informed consent must be obtained. 2) Men of any age 3) Diagnosis of prostate cancer that is clinically localized 4) Patients must be eligible for permanent prostate brachytherapy either alone or with combination of other treatments (i.e. External beam radiation or hormonal therapy)

Exclusion Criteria:

• Refusal to participate in the study

• Prior use of alpha-blocker or anti-cholinergic medication in the treatment of prostate hypertrophy.

• Contraindication to using an alpha-blocker